STAT+: Sarepta to seek early FDA approval for gene therapy to treat Duchenne muscular dystrophy
Sarepta Therapeutics said Friday that it intends seek regulators’ approval for its gene therapy to treat Duchenne muscular dystrophy earlier than expected — a risky move but one that could help the company reach the market much faster.
In early Friday trading, Sarepta shares rose 12% to $96.50.
Continue to STAT+ to read the full story…
